228 related articles for article (PubMed ID: 25612993)
41. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
42. Anti-CTLA-4 antibody adjuvant therapy in melanoma.
Eggermont AM; Testori A; Maio M; Robert C
Semin Oncol; 2010 Oct; 37(5):455-9. PubMed ID: 21074060
[TBL] [Abstract][Full Text] [Related]
43. Randomized trials in melanoma: an update.
Eggermont AM
Surg Oncol Clin N Am; 2006 Apr; 15(2):439-51. PubMed ID: 16632225
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic monoclonal antibodies in human breast milk: a case study.
Ross E; Robinson SE; Amato C; McMillan C; Westcott J; Wolf T; Robinson WA
Melanoma Res; 2014 Apr; 24(2):177-80. PubMed ID: 24476799
[TBL] [Abstract][Full Text] [Related]
45. Ipilimumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1511-21. PubMed ID: 23181437
[TBL] [Abstract][Full Text] [Related]
46. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis.
Venditti O; De Lisi D; Caricato M; Caputo D; Capolupo GT; Taffon C; Pagliara E; Battisi S; Frezza AM; Onetti Muda A; Tonini G; Santini D
BMC Cancer; 2015 Mar; 15():87. PubMed ID: 25885696
[TBL] [Abstract][Full Text] [Related]
47. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
[TBL] [Abstract][Full Text] [Related]
48. [Immunotherapies and melanoma].
Routier É; Robert C; Mateus C
Bull Cancer; 2014 Dec; 101 Suppl 2():S13-24. PubMed ID: 25776763
[TBL] [Abstract][Full Text] [Related]
49. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
50. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
Barjaktarevic IZ; Qadir N; Suri A; Santamauro JT; Stover D
Chest; 2013 Mar; 143(3):858-861. PubMed ID: 23460165
[TBL] [Abstract][Full Text] [Related]
51. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
[TBL] [Abstract][Full Text] [Related]
52. Ipilimumab and its toxicities: a multidisciplinary approach.
Fecher LA; Agarwala SS; Hodi FS; Weber JS
Oncologist; 2013 Jun; 18(6):733-43. PubMed ID: 23774827
[TBL] [Abstract][Full Text] [Related]
53. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
54. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
[TBL] [Abstract][Full Text] [Related]
55. Ipilimumab: a novel treatment for metastatic melanoma.
Culver ME; Gatesman ML; Mancl EE; Lowe DK
Ann Pharmacother; 2011 Apr; 45(4):510-9. PubMed ID: 21505108
[TBL] [Abstract][Full Text] [Related]
56. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.
Harmankaya K; Erasim C; Koelblinger C; Ibrahim R; Hoos A; Pehamberger H; Binder M
Med Oncol; 2011 Dec; 28(4):1140-4. PubMed ID: 20593249
[TBL] [Abstract][Full Text] [Related]
57. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
58. Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure.
Pretto F; Neri D
Pharmacol Ther; 2013 Sep; 139(3):405-11. PubMed ID: 23711792
[TBL] [Abstract][Full Text] [Related]
59. Ipilimumab in a patient with known Crohn's disease: to give or not to give?
Gielisse EA; de Boer NK
J Crohns Colitis; 2014 Dec; 8(12):1742. PubMed ID: 25154682
[No Abstract] [Full Text] [Related]
60. Melanoma-associated retinopathy treated with ipilimumab therapy.
Audemard A; de Raucourt S; Miocque S; Comoz F; Giraud JM; Dreno B; Bienvenu B; Rogerie MJ; Dompmartin A
Dermatology; 2013; 227(2):146-9. PubMed ID: 24051549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]